| 產(chǎn)品編號(hào) | bs-4593R-Cy3 |
| 英文名稱(chēng)1 | Rabbit Anti-MMP9/Cy3 Conjugated antibody |
| 中文名稱(chēng) | Cy3標(biāo)記的基質(zhì)金屬蛋白酶9抗體 |
| 別 名 | Matrix metalloproteinase-9 precursor; MMP-9; MMP9; MMP 9; 92 kDa type IV; Collagenase; 92 kDa gelatinase; Gelatinase B; GELB; MMP9_HUMAN; 82 kDa matrix metalloproteinase-9; 92 kDa type IV collagenase; CLG 4B; CLG-4B; CLG4B; Collagenase Type 4 beta; Collagenase Type-4 beta; Collagenase type IV 92 KD; Collagenase type IV 92 KD; EC 3.4.24.35; Gelatinase 92 KD; Gelatinase 92 KD; Gelatinase beta; Gelatinase-beta; GelatinaseB; GELB; Macrophage gelatinase; MANDP2; Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase); Matrix Metalloproteinase 9; Type V collagenase. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買(mǎi) 大包裝/詢(xún)價(jià) |
| 說(shuō) 明 書(shū) | 100ul |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 免疫學(xué) 神經(jīng)生物學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 轉(zhuǎn)錄調(diào)節(jié)因子 合成與降解 |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 交叉反應(yīng) | Human, Dog, (predicted: Mouse, Rat, Chicken, Pig, Horse, Rabbit, Sheep, ) |
| 產(chǎn)品應(yīng)用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 78kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human MMP9 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: All cells within tissues are surrounded by an extracellular matrix (ECM) giving the tissues shape and structure. The ECM is constantly being remodeled and constant communication is maintained between cells through this matrix. Secreted proteins, termed matrix metalloproteinases (MMPs), are involved in the modulation of cell matrix interactions. MMPs are Zn(2+) binding endopeptidases that degrade various components of the ECM. MMPs are enzymes implicated in normal and pathologic tissue remodeling processes, wound healing, angiogenesis, and tumor invasion. These enzymes are very potent when active, and are associated with extracellular space inhibitors called TIMPs (tissue inhibitors of matrix metalloproteinases). TIMPs have been shown to block tumor cell invasion suggesting that they act as metastasis suppressor genes. Function: May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu bond. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide. Subunit: Exists as monomer or homodimer; disulfide-linked. Exists also as heterodimer with a 25 kDa protein. Macrophages and transformed cell lines produce only the monomeric form. Interacts with ECM1. Subcellular Location: Secreted, extracellular space, extracellular Tissue Specificity: Produced by normal alveolar macrophages and granulocytes. Post-translational modifications: Processing of the precursor yields different active forms of 64, 67 and 82 kDa. Sequentially processing by MMP3 yields the 82 kDa matrix metalloproteinase-9. N- and O-glycosylated. DISEASE: Defects in MMP9 may be a cause of susceptibility to intervertebral disc disease (IDD) [MIM:603932]; also known as lumbar disk herniation (LDH). IDD is one of the most common musculo-skeletal disorders and the predominant cause of low-back pain and unilateral leg pain. Defects in MMP9 are the cause of metaphyseal anadysplasia type 2 (MANDP2) [MIM:613073]. Metaphyseal anadysplasia consists of an abnormal bone development characterized by severe skeletal changes that, in contrast with the progressive course of most other skeletal dysplasias, resolve spontaneously with age. Clinical characteristics are evident from the first months of life and include slight shortness of stature and a mild varus deformity of the legs. Patients attain a normal stature in adolescence and show improvement or complete resolution of varus deformity of the legs and rhizomelic micromelia. Similarity: Belongs to the peptidase M10A family. Database links: Entrez Gene: 4318 Human Entrez Gene: 17395 Mouse Omim: 120361 Human SwissProt: P14780 Human SwissProt: P41245 Mouse Unigene: 297413 Human Unigene: 4406 Mouse Unigene: 10209 Rat
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. MMP9亦稱(chēng)IV型膠原酶或明膠酶B，其主要功能為降解IV型膠原。因而它在腫瘤細(xì)胞突破基底膜屏障和浸潤(rùn)轉(zhuǎn)移中起重要作用。目前主要用于各種惡性腫瘤(如乳腺癌、胃腸道癌、卵巢癌、膀胱癌等)中的基底膜檢測(cè)與轉(zhuǎn)移浸潤(rùn)的研究。細(xì)胞外基質(zhì)在維持正常組織結(jié)構(gòu)與功能以及細(xì)胞生長(zhǎng)和分化過(guò)程中起重要作用。細(xì)胞外基質(zhì)動(dòng)態(tài)平衡的失調(diào)與腫瘤細(xì)胞侵襲、轉(zhuǎn)移和復(fù)發(fā)密切相關(guān)，基質(zhì)金屬蛋白酶(MMP9)是細(xì)胞外基質(zhì)的降解酶，可降解Ⅳ、Ⅴ、Ⅸ、Ⅺ型膠原，在腫瘤的浸潤(rùn)、轉(zhuǎn)移過(guò)程中起重要作用，近年為腫瘤研究的熱點(diǎn)。 |
